Ebru Damadoğlu

Giresun Hamdi Bozbağ Anadolu Lisesi'nden 1995'te, Marmara Üniversitesi Tıp Fakültesi'nden 2002'de mezun olmuş, 2002- 2008 yıllarında S.B.Süreyyapaşa Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi'nde göğüs hastalıkları uzmanlık eğitimini tamamlamıştır. Şanlıurfa Devlet Hastanesi'nde mecburi hizmet yapmış, Hacettepe Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı 'da,2011 yılındaAllerji ve İmmünoloji Hastalıkları yan daluzmanlık eğitimini tamamlamıştır. Aynı Anabilim Dalı'nda bu tarihten sonra çalışmalarına devam etmiştir. Amsterdam Üniversitesi, Academic Medical Center'da 2017 yılında 6 ay süreyle, indükte balgam ve nasal lavaj analizi konularındaeğitim almıştır.2015 yılında Doçent, 2022 yılında Profesör ünvanını almıştır.

1. Determination of the yearly distribution of the incidence of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients registered in the cystic fibrosis patient registry system of Turkey and identification of risk factors for its developmentDemir H. İ., Yalçın E., Büyükşahin H. N., Savaş S., Şen V., Şen H. S., et al.Chronic Illness, cilt.22, sa.3, ss.229-239, 2026 (SCI-Expanded, SSCI, Scopus)
2. Managing multimorbidity in severe asthma: comparison of resources and perspectives between severe asthma specialists and general respiratory physicians across EuropeMatīsa D., Bansal A. T., Rink S., Freeman A., Frankemölle B., Singh M., et al.ERJ Open Research, cilt.12, sa.5, 2026 (SCI-Expanded, Scopus)
3. Rapid Drug Desensitization to Platinum-based Chemotherapy Agents: A Single-center ExperienceKAYIKÇI H., DAMADOĞLU E., CİHANBEYLERDEN M., Tüccar Ç., Ustaoğlu A. P., ÇAYIRÖZ K., et al.Thoracic Research and Practice, cilt.27, sa.5, ss.317-323, 2026 (ESCI, Scopus, TRDizin)
4. Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma RegistryFouka E., Bansal A. T., Håkansson K. E. J., Jaun F., Louis R., Hanon S., et al.The Lancet Respiratory Medicine, cilt.14, sa.8, ss.659-672, 2026 (SCI-Expanded, Scopus)
5. A qualitative study on the experiences and perspectives of adults with cystic fibrosis and healthcare professionalsAkyazi N., Kemer S. N., Yagli N. V., SAĞLAM M., DAMADOĞLU E., KARCIOĞLU O., et al.Respiratory Medicine, cilt.260, 2026 (SCI-Expanded, Scopus)
6. Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patientsAkman Ar E. D., Yalçın N., Balaban U., Karcıoğlu O., Damadoğlu E., Kalyoncu A. F., et al.Pulmonary Pharmacology and Therapeutics, cilt.93, 2026 (SCI-Expanded, Scopus)
7. The association between baseline IgE level and urticaria control at six months of omalizumab treatment in chronic urticariaTUNCAY G., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.European Annals of Allergy and Clinical Immunology, cilt.58, sa.3, ss.126-133, 2026 (ESCI, Scopus)
8. Clinical outcomes and risk factors associated with breakthrough reactions in chemotherapy desensitizationKAYIKÇI H., DAMADOĞLU E., CİHANBEYLERDEN M., Tuccar C., Pehlivanlar Ustaoglu A., ÇAYIRÖZ K., et al.Allergy and asthma proceedings, cilt.47, sa.3, ss.216-224, 2026 (SCI-Expanded, Scopus)
9. Multimorbidity phenotypes and associated characteristics in severe asthma: an observational study of European severe asthma registriesFreeman A., Rink S., Bansal A. T., Frankemölle B., Singh M., Sont J. K., et al.The Lancet Regional Health - Europe, cilt.63, 2026 (SCI-Expanded, SSCI, Scopus)
10. Türkiye Romatoloji Derneği ANCA ilişkili (asosiye) vaskülitler hastalık yönetimi kılavuzuKaradag O., Duran E., Dağlı P. A., Gerçik Ö., Kardaş R. C., sahin d., et al.Ulusal Romatoloji Dergisi, cilt.18, sa.1, ss.10-23, 2026 (TRDizin)
11. Comparison of the characteristics of patients with chronic urticaria receiving standard-or high-dose omalizumabTUNCAY G., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.European Annals of Allergy and Clinical Immunology, cilt.58, sa.2, ss.69-76, 2026 (ESCI, Scopus)
12. Identifying future risk factors of uncontrolled asthma control: the TAAR study perspectiveBOZKURT N., Abadoglu O., Onaran A. B. O., GÖKMEN D., Buhari G. K., AYDIN Ö., et al.Journal of Asthma, cilt.63, sa.3, ss.339-349, 2026 (SCI-Expanded, Scopus)
13. Comparison of Clinical Characteristics Between Hereditary Angioedema Patients Aged 65 Years and Older and Those Under 65: A Perspective on Elderly PatientsTuncay G., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.Life, cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)
14. Turkish language validity and reliability of the severe asthma Questionnaire (SAQ)GEMİCİOĞLU B., Celik G., DAMADOĞLU E., Efe O., Yıldırım O., Vardaloglu I., et al.Journal of Asthma, cilt.63, sa.2, ss.232-241, 2026 (SCI-Expanded, Scopus)
15. Lung function outcomes of cystic fibrosis patients after early-life pulmonary exacerbations: National registry analysisÖzkan Tabakçı S., Uytun S., Eryılmaz Polat S., Cinel G., Yalçın E., KİPER E. N., et al.Pediatrics International, cilt.68, sa.1, 2026 (SCI-Expanded, Scopus)
16. Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic UrticariaKAYIKÇI H., DAMADOĞLU E., Cihanbeylerden M., Tüccar Ç., Ustaoğlu A. P., KARAKAYA G., et al.Allergy: European Journal of Allergy and Clinical Immunology, cilt.81, sa.1, ss.267-270, 2026 (SCI-Expanded, Scopus)
17. Are adult cystic fibrosis patients satisfied with medication treatment?AKMAN AR E. D., YALÇIN N., KARCIOĞLU O., DAMADOĞLU E., KALYONCU A. F., Demirkan K.ORPHANET JOURNAL OF RARE DISEASES, cilt.20, sa.1, 2025 (SCI-Expanded, Scopus)
18. Current Status of Cystic Fibrosis in Türkiye: Data from the National RegistryTural D. A., Eyuboglu T. S., CINEL G., Cakir E., PEKCAN S., Özçelik U., et al.THORACIC RESEARCH AND PRACTICE, cilt.26, sa.5, ss.238-247, 2025 (ESCI, Scopus, TRDizin)
19. What Does Radiologic Assessment Contribute to Asthma: A Subanalysis of the Turkish Adult Asthma RegistryKIZILIRMAK D., Uzun O., GÖKMEN D., AYDIN Ö., BAŞYİĞİT İ., DURSUN A. B., et al.BRATISLAVA MEDICAL JOURNAL, cilt.126, ss.1008-1022, 2025 (SCI-Expanded, Scopus)
20. Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic UrticariaCihanbeylerden M., Teixeira J., Kayikci H., Tuccar C., Kalyoncu A. F., Damadoglu E., et al.ALLERGY, cilt.80, sa.5, ss.1495-1497, 2025 (SCI-Expanded, Scopus)
21. Future of allergy and immunology Is artificial intelligence the key in the digital era?Goktas P., DAMADOĞLU E.ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, cilt.134, sa.4, ss.396-0, 2025 (SCI-Expanded, Scopus)
22. Evaluation of Risk Factors Causing Diagnostic Delay in Non-steroidal Anti-inflammatory Drug-exacerbated Respiratory DiseaseCİHANBEYLERDEN M., KAYIKÇI H., Tuccar C., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.THORACIC RESEARCH AND PRACTICE, cilt.26, sa.2, ss.77-84, 2025 (ESCI, Scopus, TRDizin)
23. Clinical characteristics and biological treatment responses of patients with late-onset asthma phenotypeKAYIKÇI H., DAMADOĞLU E., CİHANBEYLERDEN M., Tuccar C., KARAKAYA G., KALYONCU A. F.ALLERGY AND ASTHMA PROCEEDINGS, cilt.46, sa.2, ss.109-118, 2025 (SCI-Expanded, Scopus)
24. Socioeconomic status has direct impact on asthma control: Turkish adult asthma registryARSLAN B., TÜRK M., HAYME S., AYDIN Ö., GÖKMEN D., Buhari G. K., et al.CLINICAL AND TRANSLATIONAL ALLERGY, cilt.15, sa.1, 2025 (SCI-Expanded, Scopus)
25. Outcomes of Modulator Therapy Discontinued After Short-Term Use in Adult Cystic FibrosisKARCIOĞLU O., Idikut A., ÖZTÜRK E., DAMADOĞLU E.PEDIATRIC PULMONOLOGY, cilt.60, sa.1, 2025 (SCI-Expanded, Scopus)
26. Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registryGEMİCİOĞLU B., GÖKMEN D., Can A., SEVİNÇ C., OĞUZÜLGEN İ. K., SOYYİĞİT Ş., et al.RESPIRATORY MEDICINE, cilt.236, 2025 (SCI-Expanded, Scopus)
27. Development of a scoring system to predict postoperative pulmonary complications in a tertiary care centerDegirmenci C., DEMİR A. U., Coplu L., DAMADOĞLU E.MARMARA MEDICAL JOURNAL, cilt.38, sa.2, ss.141-149, 2025 (ESCI, Scopus, TRDizin)
28. Asthma patients with obesity have a unique phenotype: a subanalysis of the Turkish adult asthma registryÇELEBİ SÖZENER Z., OĞUZÜLGEN İ. K., Ozalp Ates F. S., BAÇÇIOĞLU A., ARGUN BARIŞ S., EDİGER D., et al.JOURNAL OF ASTHMA, cilt.62, ss.1183-1194, 2025 (SCI-Expanded, Scopus)
29. Establishment of 3D cell culture systems with decellularized lung-derived extracellular matrix hydrogel scaffoldSubasi Can S., Tuncer S., AKEL BİLGİÇ H., Imrak G., Guenal G., DAMADOĞLU E., et al.JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION, cilt.36, ss.22-44, 2025 (SCI-Expanded, Scopus)
30. Trends in prescribing montelukast in patients with asthma in real-life: Results from the Turkish adult asthma registryBeyaz S., Erdinc M., HAYME S., Aslan A. F., Aydin O., Gokmen D., et al.ALLERGOLOGIA ET IMMUNOPATHOLOGIA, cilt.53, sa.1, ss.12-25, 2025 (SCI-Expanded, Scopus)
31. Evaluation of Post-Transfer Clinical Status of Cystic Fibrosis Patients Transferred to Adult Chest Diseases ClinicOzdemir H. Y., KARCIOĞLU O., DAMADOĞLU E., KALYONCU A. F.PEDIATRIC PULMONOLOGY, cilt.60, sa.1, 2025 (SCI-Expanded, Scopus)
32. Factors associated with pulmonary function decline of patients in the cystic fibrosis registry of Turkey: A retrospective cohort studyEMİRALİOĞLU ORDUKAYA N., ÇAKIR B., SERTÇELİK A., Yalcin E., Kiper N., ŞEN V., et al.PEDIATRIC PULMONOLOGY, cilt.59, ss.2956-2966, 2024 (SCI-Expanded, Scopus)
33. Evaluation of treatment satisfaction and related factors in adult cystic fibrosis patientsAKMAN AR E. D., YALÇIN N., Aydin D., DAMADOĞLU E., KALYONCU A. F., Demirkan K.EUROPEAN RESPIRATORY JOURNAL, 2024 (SCI-Expanded, Scopus)
34. Comparison of the Efficacy of Omalizumab and Mepolizumab in Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory DiseaseCİHANBEYLERDEN M., TUNCAY G., KAYIKÇI H., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, cilt.185, ss.947-952, 2024 (SCI-Expanded, Scopus)
35. Successful desensitization in a patient with recurrent anaplastic oligodendroglioma presenting with procarbazine-mediated anaphylaxisKAYIKÇI H., Can Bostan Ö., TUNCAY G., CİHANBEYLERDEN M., Tüccar Ç., DAMADOĞLU E., et al.Journal of Oncology Pharmacy Practice, cilt.30, sa.5, ss.937-940, 2024 (SCI-Expanded, Scopus)
36. Clinical features, severity, and immunological changes during venom immunotherapy in children and adultsBuyuktiryaki B., Hela F., Ozturk A. B., DURSUN A. B., DÖNMEZ H., Gelincik A., et al.ALLERGY AND ASTHMA PROCEEDINGS, cilt.45, sa.4, ss.276-283, 2024 (SCI-Expanded, Scopus)
37. Efficacy and safety of hymenoptera venom immunotherapyKAYIKÇI H., Bostan O. C., TUNCAY G., CİHANBEYLERDEN M., DAMADOĞLU E., KARAKAYA G., et al.ALLERGY AND ASTHMA PROCEEDINGS, cilt.45, sa.4, ss.268-275, 2024 (SCI-Expanded, Scopus)
38. Assessment of clinical phenotypic characteristics of patients with angioedema without wheals in a turkish populationCakmak M. E., Bostan O. C., KAYA S. B., KARAKAYA G., KALYONCU A. F., DAMADOĞLU E.ALLERGY AND ASTHMA PROCEEDINGS, cilt.45, sa.4, ss.240-246, 2024 (SCI-Expanded, Scopus)
39. The respiratory assessment of cirrhotic patients: six-minute walk test is an independent predictor of mortality in cirrhosisGÜRBÜZ B., Idikut A., Karakulak U., DAMADOĞLU E., Kaya B., KAV T., et al.JOURNAL OF HEPATOLOGY, 2024 (SCI-Expanded, Scopus)
40. Inhaler Steroid Use Changes Oral and Airway Bacterial and Fungal Microbiome Profile in Asthma PatientsOĞUZÜLGEN İ. K., Öztürk A. B., Bacceoǧlu A., Aydln Ö., Köycü Buhari G., DAMADOĞLU E., et al.International Archives of Allergy and Immunology, cilt.185, sa.1, ss.10-19, 2024 (SCI-Expanded, Scopus)
41. Elderly and aged asthma have different characteristics: results of a multicenter studyDAMADOĞLU E., ÖZTÜRK AKTAŞ Ö., GEMİCİOĞLU B., Yilmaz N., Bozkuş F., Ayhan V., et al.Turkish Journal of Medical Sciences, cilt.54, sa.1, ss.309-315, 2024 (SCI-Expanded, Scopus, TRDizin)
42. Dual biologics therapy in a patient with severe asthma and chronic urticaria: a case report and review of the literatureCAN BOSTAN Ö., KARAKAYA G., KALYONCU A. F., DAMADOĞLU E.Journal of Asthma, cilt.61, sa.3, ss.260-264, 2024 (SCI-Expanded, Scopus)
43. Stepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management GroupÇELİK G. E., AYDIN Ö., DAMADOĞLU E., Baççıoğlu A., Özdemir S. K., BAVBEK S., et al.Thoracic Research and Practice, cilt.24, sa.6, ss.309-324, 2023 (ESCI, Scopus, TRDizin)
44. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU studyKocatürk E., Salameh P., Sarac E., Vera Ayala C. E., Thomsen S. F., Zuberbier T., et al.Journal of Allergy and Clinical Immunology, cilt.152, sa.5, ss.1095-1106, 2023 (SCI-Expanded, Scopus)
45. Reply to “Artificial intelligence's potential in tailoring prescription of biological therapy for chronic rhinosinusitis”Goktas P., KARAKAYA G., KALYONCU A. F., DAMADOĞLU E.Journal of Allergy and Clinical Immunology: In Practice, cilt.11, sa.10, ss.3286-3287, 2023 (SCI-Expanded, Scopus)
46. Patients with cystic fibrosis who could not receive the CFTR modulator treatment: What did they lose in 1 year?Uytun S., Cinel G., Eryılmaz Polat S., Özkan Tabakçı S., KİPER E. N., Yalçın E., et al.Pediatric Pulmonology, cilt.58, sa.9, ss.2505-2512, 2023 (SCI-Expanded, Scopus)
47. Artificial Intelligence Chatbots in Allergy and Immunology Practice: Where Have We Been and Where Are We Going?Goktas P., KARAKAYA G., KALYONCU A. F., DAMADOĞLU E.Journal of Allergy and Clinical Immunology: In Practice, cilt.11, sa.9, ss.2697-2700, 2023 (SCI-Expanded, Scopus)
48. Evaluation of disease control after SARS-CoV-2 infection or vaccination in patients with NSAID-exacerbated airway diseaseCİHANBEYLERDEN M., CAN BOSTAN Ö., TUNCAY G., Safak C., DAMADOĞLU E., KARAKAYA G., et al.Allergy and asthma proceedings, cilt.44, sa.4, 2023 (SCI-Expanded, Scopus)
49. Thermo-SPT: A new skin prick test evaluation framework based on low-cost, portable smartphone thermographyGoktas P., CAN BOSTAN Ö., GÜLSEREN D., Cakmak M. E., KAYA S. B., DAMADOĞLU E., et al.Clinical and Experimental Allergy, cilt.53, sa.6, ss.626-635, 2023 (SCI-Expanded, Scopus)
50. Sinonasal and respiratory outcomes of eosinophilic granulomatosis with polyangiitis patients receiving 100 mg mepolizumab in real-life clinical practice: 1-year follow up study.Can Bostan Ö., Duran E., Tuncay G., Cihanbeylerden M., Karadag Ö., Damadoglu E., et al.The Journal of asthma : official journal of the Association for the Care of Asthma, cilt.60, sa.5, ss.931-937, 2023 (SCI-Expanded, Scopus)
51. A case-control study of the effects of Aspergillus clinical phenotypes on pulmonary functions in patients with cystic fibrosis.Nayir Buyuksahin H., Dogru D., Emiralioglu N., Ademhan Tural D., Özsezen B., Sunman B., et al.Pediatric pulmonology, cilt.58, sa.4, ss.1185-1193, 2023 (SCI-Expanded, Scopus)
52. The Association Between Comorbidities and a High-Risk Status According to COPD GOLD GroupsSERTÇELİK Ü. Ö., SERTÇELİK A., HUSEYNOVA K., ÖNCEL A., ÇELEBİOĞLU E., ÇÖPLÜ L.Acta Medica, cilt.54, sa.1, ss.27-34, 2023 (TRDizin)
53. Physical activity and dietary habits in patients with asthma: How is it related to asthma control?AYDIN Ö., Çelebi Sözener Z., MUNGAN V. D., Özbey Ü., BALABAN S., GÖKMEN D., et al.Obesity Medicine, cilt.38, 2023 (Scopus)
54. Comparison of 300 mg versus 600 mg daily maintenance doses of aspirin treatment after desensitization in N-ERD: A three-year multicentre experienceÇELİK G. E., KARAKAYA G., Erkekol F. O., Dursun A. B., Gelincik A., AYDIN Ö., et al.Allergy and asthma proceedings, cilt.44, sa.2, ss.106-114, 2023 (SCI-Expanded, Scopus)
55. Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysisKroes J. A., Alfonso-Cristancho R., Bansal A. T., Berret E., Bieksiene K., Bourdin A., et al.ERJ Open Research, cilt.9, sa.2, 2023 (SCI-Expanded, Scopus)
56. Short- and long-term oral steroid therapy in patients with asthma exacerbationÇakmak M. E., Kaya S. B., Bostan Ö. C., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.Monaldi Archives for Chest Disease, cilt.93, sa.1, 2023 (ESCI, Scopus)
57. Picturing asthma in Turkey: results from the Turkish adult asthma registryÇELİK G. E., AYDIN Ö., GÖKMEN D., Koycu Buhari G., Celebi Sozener Z., GEMİCİOĞLU B., et al.Journal of Asthma, cilt.60, sa.11, ss.1973-1986, 2023 (SCI-Expanded, Scopus)
58. Prevalence and clinical features of pollen-food allergy syndrome in adults with seasonal allergic rhinitisÖZDEMİR E., DAMADOĞLU E., KARAKAYA G., KALYONCU A. F.European Review for Medical and Pharmacological Sciences, cilt.27, sa.1, ss.103-109, 2023 (SCI-Expanded, Scopus)
59. Body functions and structure, activity, and participation limitations of adult cystic fibrosis patients under the international classification of functioning, disability, and health frameworkBagci R., VARDAR YAĞLI N., SAĞLAM M., ÇALIK KÜTÜKCÜ E., İNAL İNCE D., Sener F., et al.PHYSIOTHERAPY THEORY AND PRACTICE, cilt.39, sa.7, ss.1417-1427, 2023 (SCI-Expanded, Scopus)
60. Comparison of the clinical outcomes of patients with NSAID-exacerbated respiratory disease receiving aspirin or biologicals.Tuncay G., Damadoglu E., Cihanbeylerden M., Can Bostan Ö., Kayıkcı H., Özer S., et al.The Journal of asthma : official journal of the Association for the Care of Asthma, cilt.60, sa.10, ss.1885-1894, 2023 (SCI-Expanded, Scopus)

All 125 on AVESİS →

1. Cirrhotic cardiomyopathy: diagnostic challenges and debating role in mortality prediction in cirrhosisGurbuz B., Karakulak U., İDİKUT A., DAMADOĞLU E., Kaya B., ÖZTÜRK B. Ö., et al.European-Association-for-the-Study-of-the-Liver Congress, Amsterdam, Hollanda, 7 - 10 Mayıs 2025, cilt.82, (Özet Bildiri)
2. Real-world patient-level costeffectiveness analysis of omalizumab in patients with severe allergic asthmaOĞUZÜLGEN İ. K., Tugay D., TOP M., AYDIN Ö., BAVBEK S., DAMADOĞLU E., et al.Annual congress of the European-Respiratory-Society (ERS), Milan, İtalya, 9 - 13 Eylül 2023, (Özet Bildiri)
3. Evaluation of respiratory function at 6 years of age in patients with cystic fibrosis with frequent pulmonary exacerbations in the first 2 years of lifeTabakci S. O., CİNEL G., Uytun S., Polat S. E., Yalcin E., Kiper N., et al.Annual congress of the European-Respiratory-Society (ERS), Milan, İtalya, 9 - 13 Eylül 2023, (Özet Bildiri)
4. Association of dyspnea and physical activity level in adult patients with CF during COVID19Aksel A. A., Vardar Yağlı N., Fırat M., Sağlam M., Çalık Kütükcü E., Damadoğlu E.Annual Congress of the European-Respiratory-Society (ERS), Milan, İtalya, 9 - 13 Eylül 2023, (Özet Bildiri)
5. Are elderly and aged asthma different diseases? Results of a multicenter studyÇELEBİOĞLU E., Aktas O. O., GEMİCİOĞLU B., YILMAZ N., BOZKUŞ F., Ayhan V., et al.28th International Congress of the European-Respiratory-Society (ERS), Paris, Fransa, 15 - 19 Eylül 2018, cilt.52, (Özet Bildiri)
6. COMPLEMENT FACTOR I DEFICIENCY MAY PRESENT WITH RECURRENT SEIZURES AND ENCEPHALITISŞAHAN Ö., ÖZTÜRK AKTAŞ Ö., YAZ İ., DAMADOĞLU E., KARAKAYA G., ÇAĞDAŞ AYVAZ D. N., et al.
7. Profile of Patients with Inborn Errors of Immunity Managed in an Adult Transition ClinicÖZTÜRK AKTAŞ Ö., ŞAHAN Ö., DAMADOĞLU E., KARAKAYA G., ÇAĞDAŞ AYVAZ D. N., KALYONCU A. F.
8. Erişkin kistik fibrozis hastalarında meropenem ilaç düzeyi izlemiAKMAN AR E. D., YALÇIN N., KARA E., İNKAYA A. Ç., DAMADOĞLU E., KALYONCU A. F., et al.
9. Association between disease severity, asthma control and obesity in children and adultsKAHVECİ M., ÇAKMAK M., KAYA S., Soyer Ö., ÇELEBİOĞLU E., ŞAHİNER Ü. M., et al.
10. TIP III HEREDITER ANJIYOÖDEM ÖN TANILI HASTALARDA YENI NESIL DIZILEME ILE YENI GENLERIN ARAŞTIRILMASI: ÖN VERILERKoşukcu C., Uysal Soyer Ö., Karakaya G., Şahiner Ü. M., Damadoğlu E., Ocak M., et al.